Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Recurrence

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Hematinics

Antibodies

Immunoglobulins

Liver Extracts

Camrelizumab (SHR-1210), 200mg, I.V., Q3W

Camrelizumab treatment

Guoying Wang, M.D.

Wang Guoying, M.D.

This is a prospective clinical study to investigate the safety and efficacy of anti-PD-1 immunotherapy (Camrelizumab) in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation. All of the enrolled patients have a background of liver transplantation for HCC. Due to the tumor recurrence, patients are not suitable for curative surgical resection, and targeted therapy provides poor therapeutic effect, leading to tumor progression or intolerance. Before immunotherapy, the PD-L1 expression was confirmed negative in the graft liver by immunohistochemistry, and patients continued targeted therapy as part of a combined antitumor regimen. In addition, the immunosuppression schedule is also reduced to a low level.

Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation

Clinical Study of Anti-PD-1 Antibody Camrelizumab in the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation

Objective Response Rate after Camrelizumab treatment according to the mRECIST

Time from the initiation of Camrelizumab treatment to the patient death from any cause

Time from the initiation of Camrelizumab treatment to radiological tumor progression or death from any cause

Time from the initiation of Camrelizumab treatment to radiological tumor progression

The incidence of serious adverse event caused by Camrelizumab treatment

The incidence of graft rejection during the Camrelizumab treatment

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation	NCT04564313	Hepatocellular ... Liver Transplan...	Camrelizumab tr...	18 Years - 65 Years	Third Affiliated Hospital, Sun Yat-Sen University
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation	NCT04564313	Hepatocellular ... Liver Transplan...	Camrelizumab tr...	18 Years - 65 Years	Third Affiliated Hospital, Sun Yat-Sen University

Spots Global Cancer Trial Database for camrelizumab treatment